James Van Der Beek and Guardant Health have announced a groundbreaking partnership today to raise awareness about advanced colorectal cancer screening options for adults aged 45 and older. The collaboration comes as the actor publicly advocates for screening for the first time since revealing his stage 3 colorectal cancer diagnosis in November 2024.
The partnership addresses a critical healthcare gap where 75% of patients who die from colorectal cancer are not screened, often because traditional options are viewed as unpleasant or inconvenient. This alarming statistic has prompted Van Der Beek to leverage his platform to educate Americans about life-saving screening alternatives.
Table of Contents
A Personal Mission Born from Experience
Van Der Beek’s advocacy stems from his own shocking diagnosis experience. “I was 46 years old, in great physical shape, and had no idea I was living with stage 3 colorectal cancer,” the Varsity Blues star revealed. His story illustrates how this silent killer can affect anyone, regardless of apparent health status.
The actor emphasizes the urgency of early detection, noting that colorectal cancer is “the second most deadly cancer, but the most curable when caught in its early stages, making screening crucial.” This message resonates particularly strongly given that over 50,000 Americans die from the disease annually.
Revolutionary Blood-Based Screening Technology
Central to this partnership is Guardant Health’s Shield™ blood test, which represents a paradigm shift in colorectal cancer screening. The FDA-approved Shield offers screening with a simple blood draw from any prescribing healthcare provider for adults 45+ at average risk for CRC.
This innovation addresses the primary barrier preventing many Americans from getting screened. Traditional screening methods often deter patients, leaving more than 50 million people—one in three American adults age 45 and over—avoiding this potentially life-saving procedure.
Key Benefits of Shield Technology:
- Simple blood draw procedure
- Results available within two weeks
- No invasive preparation required
- Available through any prescribing healthcare provider
- First FDA-approved blood test for primary CRC screening
Clinical Impact and Medical Endorsement
Healthcare professionals are embracing this technological advancement. Dr. Angel Lazo, an internal medicine physician in New Jersey, shared his frontline perspective: “Adding the option of Shield has made it much more convenient and expanded screening to more people, giving peace of mind to them – and to me as their doctor.”
The medical community’s support extends beyond individual practitioners. The National Comprehensive Cancer Network recently included the Shield blood test in its updated colorectal cancer screening guidelines, signaling broader institutional acceptance of this screening method.
The Stakes: Lives Hanging in the Balance
The statistics surrounding colorectal cancer screening reveal both hope and urgency. The five-year survival rate exceeds 90% when CRC is caught in its early stages, but plummets to 13% in late stages when symptoms usually appear. This dramatic difference underscores why Van Der Beek’s advocacy work carries such weight.
AmirAli Talasaz, Guardant Health co-CEO, emphasized the partnership’s mission: “Our goal is to ensure that everyone who should be screened for colorectal cancer gets screened – and the Shield blood test is a major step forward in making screening more convenient and accessible across the country.”
Breaking Down Screening Barriers
James Van Der Beek and Guardant Health recognize that convenience plays a crucial role in screening compliance. The actor’s personal experience reinforces this understanding: “I was relieved to learn about Guardant’s Shield blood test because it’s a more pleasant and convenient way to get screened, especially for those who’ve been hesitating.”
This partnership represents more than a celebrity endorsement—it’s a genuine effort to save lives through education and accessibility. Van Der Beek’s candid approach to sharing his cancer journey provides authenticity that resonates with audiences who might otherwise avoid discussing screening options.
Looking Forward: Expanding Access and Awareness
The collaboration between Van Der Beek and Guardant Health comes at a pivotal moment in cancer screening technology. With Shield’s recent inclusion in major clinical guidelines and growing physician adoption, this partnership could significantly impact colorectal cancer mortality rates.
Van Der Beek’s message remains direct: “Simply put, getting screened can save your life. If you’re 45 or older, make sure you talk to your doctor about screening guidelines and your options.”
This powerful alliance between Hollywood advocacy and medical innovation offers hope for reducing colorectal cancer deaths through increased screening participation. As Van Der Beek continues his own cancer journey, his partnership with Guardant Health ensures that his experience becomes a catalyst for saving other lives through early detection.
What are your thoughts on how celebrity advocacy can impact public health awareness? Share your experiences with cancer screening or let us know how this partnership might influence your health decisions.